By Scientia Professor Gregory John Dore

Journal articles

Marcellin P; Reddy KR; Roberts SK; Jensen DM; Harrison SA; Hadziyannis SJ; Dore G; Diago M; Weltman MD; Solsky J; Tietz A; Rizzetto M, 2010, 'T1990 Peginterferon Alfa-2a (40KD) Has a Wide Safety Margin in Patients Infected With Hepatitis C Virus Genotype 1: Pooled Data From Four Randomized Multicenter Studies', Gastroenterology, 138, pp. S - 844, http://dx.doi.org/10.1016/s0016-5085(10)63886-3

Haber P; Hellard M; Matthews GV; Grebely J; Petoumenos K; Yeung B; Marks P; Van Beek I; Kaldor J; Dore GJ, 2009, 'TREATMENT OF RECENT HEPATITIS C VIRUS INFECTION IN A PREDOMINANTLY INJECTION DRUG USER COHORT: THE ATAHC STUDY', DRUG AND ALCOHOL REVIEW, 28, pp. A27 - A27, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270916300083&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Bouchez V; Brun D; Cantinelli T; Dore G; Njamkepo E; Guiso N, 2009, 'First report and detailed characterization of B. pertussis isolates not expressing pertussis toxin or pertactin', Vaccine, 27, pp. 6034 - 6041, http://dx.doi.org/10.1016/j.vaccine.2009.07.074

Matthews GV; Hellard M; Dore GJ, 2009, 'Reply', Clinical Infectious Diseases, 49, pp. 319, http://dx.doi.org/10.1086/600059

van de Laar T; Pybus O; Bruisten S; Brown D; Nelson M; Bhagani S; Vogel M; Baumgarten A; Chaix M; Fisher M; Gotz H; Matthews G; Neifer S; White PA; Rawlinson W; Pol S; Rockstroh J; Coutinho RA; Dore GJ; Dusheiko GM; Danta M, 2009, 'Evidence of a Large, International Network of HCV Transmission in HIV-Positive Men Who Have Sex With Men', Gastroenterology, 136, pp. 1609 - 1617, http://dx.doi.org/10.1053/j.gastro.2009.02.006

Robotin M; Kansil M; Howard K; George J; Tipper S; Dore GJ; Levy MT; Penman A, 2009, 'Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer', Journal of Hepatology, 50, pp. 990 - 998, http://dx.doi.org/10.1016/j.jhep.2008.12.022

Matthews G; Hellard M; Haber P; Yeung B; Marks PB; Baker D; McCaughan G; Sasadeusz J; White PA; Rawlinson WD; Lloyd AR; Kaldor JM; Dore GJ; Dolan K, 2009, 'Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in acute hepatitis C', Clinical Infectious Diseases, 48, pp. 650 - 658, http://dx.doi.org/10.1086/596770

Doab A; Topp L; Day C; Dore G; Maher L, 2009, 'Clinical trial literacy among injecting drug users in Sydney, Australia: A pilot study', Contemporary Clinical Trials, 30, pp. 431 - 435

Matthews G; Seaberg E; Dore GJ; Bowden S; Lewin S; Sasadeusz J; Marks P; Goodman Z; Philp F; Tang Y; Locarnini S; Thio C, 2009, 'Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals', AIDS, 23, pp. 1707 - 1715, http://dx.doi.org/10.1097/QAD.0b013e32832b43f2

Grebely J; Thomas D; Dore GJ, 2009, 'HCV reinfection studies and the door to vaccine development', Journal of Hepatology, 51, pp. 628 - 631

Nguyen VT; Law MG; Dore GJ, 2009, 'Hepatitis B-related hepatocellular carcinoma: Epidemiological characteristics and disease burden', Journal of Viral Hepatitis, 16, pp. 453 - 463, http://dx.doi.org/10.1111/j.1365-2893.2009.01117.x

Matthews G; Dore GJ, 2009, 'HIV and hepatitis C co-infection', Asian Biomedicine, 3, pp. 29 - 37

Suppiah V; Moldovan M; Ahlenstiel G; Berg T; Weltman M; Abate M; Bassendine M; Spengler U; Dore GJ; Powell E; Riordan SM; Sheridan D; Smedile A; Fragomeli V; Muller T; Bahlo M; Stewart GJ; Booth D; George J, 2009, 'IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy', Nature Genetics, 41, pp. 1100 - 1104, http://www.nature.com/ng/journal/v41/n10/abs/ng.447.html

Crane M; Oliver B; Matthews G; Avihingsanon A; Ubolyam S; Markovska V; Chang JJ; Dore GJ; Price P; Visvanathan K; French MA; Ruxrungtham K; Lewin S, 2009, 'Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy', Journal of Infectious Diseases, 199, pp. 974 - 981

Roberts S; Weltman M; Crawford D; Mccaughan GW; Sievert W; Cheng W; Rawlinson WD; Desmond PV; Marks P; Yoshihara M; Rizkalla B; DePamphilis J; Dore GJ, 2009, 'Impact of High-Dose Peginterferon Alfa-2A on Virological Response Rates in Patients with Hepatitis C Genotype 1: a Randomized Controlled Trial', Hepatology, 50, pp. 1045 - 1055

Chang JH; Sirivichayakul S; Avihingsanon A; Thompson A; Revill P; Iser D; Slavin J; Buranapraditkun S; Marks P; Matthews G; Cooper DA; Kent SJ; Cameron P; Sasadeusz J; Desmond PV; Locarnini S; Dore GJ; Ruxrungtham K; Lewin S, 2009, 'Impaired Quality of the Hepatitis B Virus (HBV)-Specific T-Cell Response in Human Immunodeficiency Virus Type 1-HBV Coinfection', Journal of Virology, 83, pp. 7649 - 7658

Matthews G; Hellard M; Dore GJ, 2009, 'Initial Presentation of Acute Hepatitis C Virus (HCV) Infection among HIV-Negative and HIV-Positive Individuals-Experience from 2 Large German Networks on the Study of Acute HCV Infection Reply', Clinical Infectious Diseases, 49, pp. 319 - 319, http://dx.doi.org/10.1086/600059

Razali K; Amin J; Dore GJ; Law MG, 2009, 'Modelling and calibration of the hepatitis C epidemic in Australia', Statistical Methods in Medical Research, 18, pp. 253 - 270

Topp L; Day C; Dore G; Maher L, 2009, 'Poor criterion validity of self-reported hepatitis B infection and vaccination status among injecting drug users: A review', Drug and Alcohol Review, 28, pp. 669 - 675, http://dx.doi.org/10.1111/j.1465-3362.2009.00060.x

Nguyen VT; Amin J; Law MG; Dore GJ, 2009, 'Predictors and survival in hepatitis B-related hepatocellular carcinoma in New South Wales, Australia', Journal of Gastroenterology and Hepatology, 24, pp. 436 - 442, http://dx.doi.org/10.1111/j.1440-1746.2008.05577.x

Grebely J; Knight E; Ngai T; Genoway KA; Raffa JD; Storms M; Gallagher L; Krajden M; Dore GJ; Duncan F; Conway B, 2009, 'Reinfection with hepatitis C virus following sustained virological response in injection drug users', Journal of Gastroenterology and Hepatology, pp. no - no, http://dx.doi.org/10.1111/j.1440-1746.2009.06238.x

Gidding H; Topp L; Middleton M; Robinson K; Hellard M; McCaughan G; Maher L; Kaldor J; Dore G; Law M, 2009, 'The epidemiology of hepatitis C in Australia: Notifications, treatment uptake and liver transplantations, 1997-2006', Journal of Gastroenterology and Hepatology, 24, pp. 1648 - 1654, http://dx.doi.org/10.1111/j.1440-1746.2009.05910.x

Haber P; Hellard M; Matthews GV; Grebely J; Petoumenos K; Yeung B; Marks P; van Beek I; McCaughan G; White PA; Ffrench R; Rawlinson W; Lloyd A; Kaldor J; Dore GJ, 2009, 'Treatment of recent hepatitis C virus infection in a predominantly injection drug user cohort: the ATAHC Study', The Canadian Journal of Addiction, 1, pp. 33 - 33, http://dx.doi.org/10.1097/02024458-200912000-00072

Thein H; Dore GJ, 2009, 'Trends in chronic viral hepatitis: Notifications, treatment uptake and advanced disease burden', Cancer Forum, 33, pp. 97 - 105

Lewin S; Ribiero R; Avihingsanon A; Bowden S; Matthews G; Marks P; Locarnini S; Ruxrungtham K; Perelson AS; Dore GJ, 2009, 'Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: Similar effectiveness of lamivudine, tenofovir, or combination therapy', Hepatology, 49, pp. 1113 - 1121

Grebely J; Raffa JD; Lai C; Kerr T; Krajden M; Kerr T; Dore GJ; Tyndall MW, 2008, 'Impact of HCV and HIV infections on mortality in a large community-based cohort of inner city residents', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 23, pp. A379 - A380, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600118&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Doré G; Leclerc C; Lazarini F, 2008, 'Treatment by CpG or Flt3-ligand does not affect mouse susceptibility to BSE prions', Journal of Neuroimmunology, 197, pp. 74 - 80, http://dx.doi.org/10.1016/j.jneuroim.2008.03.016

Jin F; Prestage GP; Dore GJ; Zablotska I; Rawstorne P; Kippax SC; Kaldor JM; Grulich AE, 2008, 'PREVALENCE, INCIDENCE AND RISK FACTORS FOR HEPATITIS C IN HIV NEGATIVE AND HIV POSITIVE HOMOSEXUAL MEN', SEXUAL HEALTH, 5, pp. 389 - 389, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000260999000039&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Crawford DHG; Roberts S; Weltman M; Cheng WSC; Sievert W; McCaughan G; Desmond P; Alston AW; DePamphilis J; Marks P; Dore GJ, 2008, '779 BASELINE FACTORS ASSOCIATED WITH RAPID AND EARLY VIROLOGICAL RESPONSES IN HCV GENOTYPE 1 PATIENTS TREATED WITH INDUCTION DOSING OF PEGYLATED INTERFERON: THE CHARIOT STUDY', Journal of Hepatology, 48, pp. S290 - S291, http://dx.doi.org/10.1016/s0168-8278(08)60781-3

Matthews G; Avihingsanon A; Lewin S; Amin J; Rerknimitr R; Petcharapirat P; Marks PB; Sasadeusz J; Cooper DA; Bowden S; Locarnini S; Ruxrungtham K; Dore GJ, 2008, 'A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand', Hepatology, 48, pp. 1062 - 1069

Nguyen VT; Law MG; Dore GJ, 2008, 'An enormous hepatitis B virus-related liver disease burden projected in Vietnam by 2025', Liver International, 28, pp. 525 - 531, http://dx.doi.org/10.1111/j.1478-3231.2007.01646.x

Preiss S; Littlejohn M; Angus PA; Thompson A; Desmond PV; Lewin S; Sasadeusz J; Matthews G; Dore GJ; Shaw T; Sozzi V; Yuen L; Lau GT; Ayres A; Thio C; Avihingsanon A; Ruxrungtham K; Locarnini S; Revill P, 2008, 'Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance', Hepatology, 48, pp. 741 - 749

Nguyen VT; Razali K; Amin J; Law MG; Dore GJ, 2008, 'Estimates and projections of hepatitis B-related hepatocellular carcinoma in Australia among people born in Asia-Pacific countries', Journal of Gastroenterology and Hepatology, 23, pp. 922 - 929, http://dx.doi.org/10.1111/j.1440-1746.2007.05065.x

Thein H; Yi Q; Dore GJ; Krahn M, 2008, 'Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression', Hepatology, 48, pp. 418 - 431, http://dx.doi.org/10.1002/hep.22375

Day C; White B; Thein H; Doab A; Dore G; Bates A; Holden J; Maher L, 2008, 'Experience of hepatitis C testing among injecting drug users in Sydney, Australia', AIDS Care - Psychological and Socio - Medical Aspects of AIDS/HIV, 20, pp. 116 - 123, http://dx.doi.org/10.1080/09540120701426524

Matthews G; Dore GJ, 2008, 'HIV and hepatitis C coinfection', Journal of Gastroenterology and Hepatology, 23, pp. 1000 - 1008

Thein H; Yi Q; Dore GJ; Krahn M, 2008, 'Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis', AIDS, 22, pp. 1979 - 1991

Tedaldi E; Peters L; Neuhaus J; Puoti M; Rockstroh J; Klein M; Dore GJ; Mocroft A; Soriano V; Clotet B; Lundgren JD, 2008, 'Opportunistic Disease and Mortality in Patients Coinfected with Hepatitis B or C Virus in the Strategic Management of Antiretroviral Therapy (SMART) Study', Clinical Infectious Diseases, 47, pp. 1468 - 1475

Roberts S; Cooksley G; Dore GJ; Robson RA; Shaw DW; Berns H; Hill G; Klumpp K; Najera I; Washington C, 2008, 'Robust antiviral activity of R1626, a novel nucleoside analog: A randomized, placebo-controlled study in patients with chronic hepatitis C', Hepatology, 48, pp. 398 - 406, http://dx.doi.org/10.1002/hep.22321

Dore GJ; Haber P, 2008, 'Tell me it ain¿t so: Patient-to-patient transmission of hepatitis C in an endoscopy clinic.', Hepatology, 48, pp. 1333 - 1335

Matthews G; Grebely J; Dore GJ, 2008, 'The role of re-infection in determining rates of spontaneous clearance after hepatitis C exposure', Journal of Hepatology, 49, pp. 305 - 307, http://dx.doi.org/10.1016/j.jhep.2008.06.005

Matthews GV; Seaberg E; Dore GJ; Lewin SR; Bowden S; Sasadeuz J; Marks P; Hoy J; Locarnini S; Thio CL, 2007, 'Combination of HBV-active antiretroviral therapy influences hbv virological suppression in an international cohort of 120 HIVHBV coinfected individuals', JOURNAL OF HEPATOLOGY, 46, pp. S194 - S194, http://dx.doi.org/10.1016/S0168-8278(07)62108-4

Matthews G; Hellard M; Kaldor JM; Lloyd AR; Dore GJ, 2007, 'Further evidence of HCV sexual transmission among HIV-positive men who have sex with men: response to Danta et al', AIDS, 21, pp. 2112 - 2113, http://dx.doi.org/10.1097/qad.0b013e3282ef3873

Thein H; Yi Q; Dore GJ; Krahn M, 2007, 'Natural history of hepatitis C virus infection in HIV-infected individuals in the era of HAART: Systematic review and meta-analysis', Hepatology, 46, pp. 840A - 841A, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000249910401616&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Dore GJ; Torriani F; Rodriguez-Torres M; Brau N; Sulkowski M; Sola Lamoglia R; Clumeck N; Mendes-Correa M; Nelson M; Godofsky E; Dieterich D; Yetzer E; Lissen E; Cooper DA, 2007, 'Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection', AIDS, 21, pp. 1555 - 1559

Thein H; Maruff P; Krahn M; Kaldor JM; Koorey D; Brew BJ; Dore GJ, 2007, 'Cognitive function, mood and health-related quality of life in hepatitis C virus (HCV)-monoinfected and HIV/HCV-coinfected individuals commencing HCV treatment', HIV Medicine, 8, pp. 192 - 202

Dore GJ, 2007, 'Enhancing hepatitis C treatment uptake and outcomes for injection drug users', Hepatology, 45, pp. 3 - 5

Hallinan R; Byrne AP; Dore GJ, 2007, 'Harm reduction, hepatitis C and opioid pharmacotherapy: an opportunity for integrated hepatitis C virus-specific harm reduction', Drug and Alcohol Review, 26, pp. 437 - 443

Zhou J; Dore GJ; Zhang F; Lim P; Chen Y, 2007, 'Hepatitis B and C virus coinfection in the TREAT asia HIV observational database', Journal of Gastroenterology and Hepatology, 22, pp. 1510 - 1518

Micallef JM; Macdonald V; Jauncey ME; Amin J; Rawlinson WD; Van Beek IA; Kaldor JM; White PA; Dore GJ, 2007, 'High Incidence of hepatitis C virus reinfection within a cohort of injecting drug users', Journal of Viral Hepatitis, 14, pp. 413 - 418

Back to profile page